{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Infection&page=15", "query": { "intervention": "Infection", "page": 15 }, "page_size": 10 }, "pagination": { "page": 15, "page_size": 10, "total_count": 5230, "total_pages": 523, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Infection&page=16&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Infection&page=14&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-29T11:59:40.805Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00002055", "title": "A Double-Blind Group Comparative Study To Evaluate the Long-Term Safety and Effectiveness of Two Different Doses of Aerosol Pentamidine in the Prophylaxis of Pneumocystis Carinii Pneumonia in AIDS Patients With Multiple Episodes of PCP", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Pneumonia, Pneumocystis Carinii", "HIV Infections" ], "interventions": [ { "name": "Pentamidine isethionate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fisons", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-10-29T11:59:40.805Z", "location_count": 4, "location_summary": "Washington D.C., District of Columbia • Chicago, Illinois • Boston, Massachusetts", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002055" }, { "nct_id": "NCT05369052", "title": "Safety and Efficacy Study of Contezolid Acefosamil and Contezolid Compared to Linezolid Administered Intravenously and Orally to Adults With Moderate or Severe Diabetic Foot Infections (DFI)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetic Foot Infection" ], "interventions": [ { "name": "contezolid acefosamil (IV)/contezolid (PO)", "type": "DRUG" }, { "name": "Linezolid (IV and PO)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MicuRx", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 865, "start_date": "2022-05-03", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-29T11:59:40.805Z", "location_count": 2, "location_summary": "Corona, California • Vista, California", "locations": [ { "city": "Corona", "state": "California" }, { "city": "Vista", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05369052" }, { "nct_id": "NCT00006578", "title": "Evaluation of Specific Infection-Fighting Cells For Prediction of Immune Response to Anti-HIV and Immune-Boosting Medication", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Ritonavir", "type": "DRUG" }, { "name": "Abacavir sulfate", "type": "DRUG" }, { "name": "Amprenavir", "type": "DRUG" }, { "name": "Lamivudine", "type": "DRUG" }, { "name": "Filgrastim", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2015-03-09", "last_synced_at": "2026-10-29T11:59:40.805Z", "location_count": 5, "location_summary": "Denver, Colorado • Miami, Florida • Chicago, Illinois + 1 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006578" }, { "nct_id": "NCT04482686", "title": "Trial of Combination Therapy to Treat COVID-19 Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "COVID", "Covid-19", "Corona Virus Infection", "Coronavirus Infection", "Coronavirus-19", "SARS-CoV2", "SARS-CoV Infection" ], "interventions": [ { "name": "Ivermectin", "type": "DRUG" }, { "name": "Doxycycline Hcl", "type": "DRUG" }, { "name": "Zinc", "type": "DIETARY_SUPPLEMENT" }, { "name": "Vitamin D3", "type": "DIETARY_SUPPLEMENT" }, { "name": "Vitamin C", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DRUG", "DIETARY_SUPPLEMENT" ], "sponsor": "ProgenaBiome", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2020-12-09", "completion_date": "2022-07-15", "has_results": false, "last_update_posted_date": "2024-09-24", "last_synced_at": "2026-10-29T11:59:40.805Z", "location_count": 1, "location_summary": "Ventura, California", "locations": [ { "city": "Ventura", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04482686" }, { "nct_id": "NCT04573270", "title": "Mesenchymal Stem Cells for the Treatment of COVID-19", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Covid19", "Prophylaxis" ], "interventions": [ { "name": "PrimePro", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Thomas Advanced Medical LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2020-04-24", "completion_date": "2020-09-01", "has_results": false, "last_update_posted_date": "2020-10-05", "last_synced_at": "2026-10-29T11:59:40.805Z", "location_count": 1, "location_summary": "Culver City, California", "locations": [ { "city": "Culver City", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04573270" }, { "nct_id": "NCT01940341", "title": "Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hepatitis B Infection Who Are Negative for Hepatitis B e Antigen", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HBeAg-negative Chronic Hepatitis B" ], "interventions": [ { "name": "TAF", "type": "DRUG" }, { "name": "TDF", "type": "DRUG" }, { "name": "TAF Placebo", "type": "DRUG" }, { "name": "TDF Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 426, "start_date": "2013-09-12", "completion_date": "2022-08-31", "has_results": true, "last_update_posted_date": "2023-09-25", "last_synced_at": "2026-10-29T11:59:40.805Z", "location_count": 14, "location_summary": "Los Angeles, California • Palo Alto, California • Pasadena, California + 10 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01940341" }, { "nct_id": "NCT00593151", "title": "Study of Safety, Tolerability, and Anti-Viral Effect of Locteron Compared to PEG-Intron in Patients With Chronic Hepatitis C", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "Locteron (controlled-release interferon alpha 2b)", "type": "OTHER" }, { "name": "pegylated IFNa2b", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "BIOLOGICAL" ], "sponsor": "Biolex Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2008-01", "completion_date": "2009-03", "has_results": false, "last_update_posted_date": "2012-02-03", "last_synced_at": "2026-10-29T11:59:40.805Z", "location_count": 5, "location_summary": "Detroit, Michigan • Dallas, Texas • San Antonio, Texas + 2 more", "locations": [ { "city": "Detroit", "state": "Michigan" }, { "city": "Dallas", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" }, { "city": "Annandale", "state": "Virginia" }, { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00593151" }, { "nct_id": "NCT04583280", "title": "A Study of Rilematovir in Infants and Children and Subsequently in Neonates Hospitalized With Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus (RSV)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Respiratory Tract Infections" ], "interventions": [ { "name": "Rilematovir", "type": "DRUG" }, { "name": "Rilematovir X mg/kg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Day", "maximum_age": "5 Years", "sex": "ALL", "summary": "1 Day to 5 Years" }, "enrollment_count": 28, "start_date": "2021-09-06", "completion_date": "2022-03-18", "has_results": true, "last_update_posted_date": "2025-02-04", "last_synced_at": "2026-10-29T11:59:40.805Z", "location_count": 5, "location_summary": "Orlando, Florida • Jackson, Mississippi • The Bronx, New York + 2 more", "locations": [ { "city": "Orlando", "state": "Florida" }, { "city": "Jackson", "state": "Mississippi" }, { "city": "The Bronx", "state": "New York" }, { "city": "Memphis", "state": "Tennessee" }, { "city": "Tacoma", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT04583280" }, { "nct_id": "NCT05215327", "title": "High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Immunization; Infection", "Transplantation Infection", "Influenza" ], "interventions": [ { "name": "High Dose Quadrivalent Inactivated Influenza Vaccine", "type": "BIOLOGICAL" }, { "name": "Standard Dose Quadrivalent Inactivated Influenza Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Vanderbilt University Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 270, "start_date": "2022-11-08", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-09-04", "last_synced_at": "2026-10-29T11:59:40.805Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05215327" }, { "nct_id": "NCT00004341", "title": "Study of Genetic and Molecular Defects in Primary Immunodeficiency Disorders", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "X-Linked Agammaglobulinemia", "X-Linked Hyper IgM Syndrome", "Wiskott-Aldrich Syndrome", "Leukocyte Adhesion Deficiency Syndrome" ], "interventions": [], "intervention_types": [], "sponsor": "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Years", "maximum_age": null, "sex": "ALL", "summary": "0 Years and older" }, "enrollment_count": null, "start_date": "1995-07", "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-10-29T11:59:40.805Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004341" } ] }